ACURX PHARMACEUT. DL-001
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more
ACURX PHARMACEUT. DL-001 (3ZO) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ACURX PHARMACEUT. DL-001 (3ZO) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ACURX PHARMACEUT. DL-001 - Net Assets Trend (None–None)
This chart illustrates how ACURX PHARMACEUT. DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ACURX PHARMACEUT. DL-001 (None–None)
The table below shows the annual net assets of ACURX PHARMACEUT. DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ACURX PHARMACEUT. DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ACURX PHARMACEUT. DL-001 Competitors by Market Cap
The table below lists competitors of ACURX PHARMACEUT. DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Elevai Labs, Inc. Common Stock
NASDAQ:ELAB
|
$387.31K |
|
CO.DON AG INH. O.N.
F:CNW
|
$387.77K |
|
Searchlight Resources Inc
PINK:SCLTF
|
$388.04K |
|
Oasis Crescent Property Fund
JSE:OAS
|
$388.09K |
|
MKB Nedsense N.V.
LSE:0ML7
|
$386.90K |
|
TRACTOR SUPPLY (TR4.SG)
STU:TR4
|
$386.81K |
|
KOMATSU
MU:KOM1
|
$386.74K |
|
Rasna Therapeutics Inc
PINK:RASP
|
$385.90K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ACURX PHARMACEUT. DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ACURX PHARMACEUT. DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ACURX PHARMACEUT. DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ACURX PHARMACEUT. DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ACURX PHARMACEUT. DL-001 (3ZO) | €- | N/A | N/A | $386.98K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |